Summary:
- The article outlines Daré Bioscience’s strategic transition toward commercializing their FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel 2%, for the treatment of bacterial vaginosis.
- It details the company's clinical pipeline development, specifically highlighting progress in therapeutic candidates for sexual health, reproductive health, and menopausal hormone therapy, such as Sildenafil Cream and DARE-HRT1.